Published in Cancer Res on July 28, 2009
DNA damage-induced heterogeneous nuclear ribonucleoprotein K sumoylation regulates p53 transcriptional activation. J Biol Chem (2012) 1.21
The prolyl-isomerase Pin1 activates the mitochondrial death program of p53. Cell Death Differ (2012) 1.20
Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem (2011) 1.16
Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res (2012) 1.10
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One (2012) 1.08
Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One (2012) 1.02
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des (2011) 0.99
NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2. J Cell Biol (2015) 0.99
Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma. Front Oncol (2012) 0.91
Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ (2014) 0.89
RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis (2014) 0.88
p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system. PLoS One (2011) 0.88
Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death Differ (2011) 0.86
Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One (2012) 0.86
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY) (2016) 0.84
Chk2 mediates RITA-induced apoptosis. Cell Death Differ (2011) 0.84
Homeodomain-interacting protein kinase-2 stabilizes p27(kip1) by its phosphorylation at serine 10 and contributes to cell motility. J Biol Chem (2011) 0.81
HIPK2 sustains apoptotic response by phosphorylating Che-1/AATF and promoting its degradation. Cell Death Dis (2014) 0.79
Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D. Oncoimmunology (2012) 0.76
RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. BMC Cancer (2014) 0.76
HIPK2 modification code for cell death and survival. Mol Cell Oncol (2014) 0.76
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 4.10
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle (2011) 2.43
MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell (2009) 2.36
PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle (2011) 2.30
MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell (2007) 2.10
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
ATM is activated by default in mitosis, localizes at centrosomes and monitors mitotic spindle integrity. Cell Cycle (2006) 1.82
Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ Res (2008) 1.75
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle (2010) 1.75
TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem (2003) 1.61
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene (2002) 1.51
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest (2009) 1.51
HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol (2007) 1.45
Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell (2009) 1.43
Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell (2006) 1.38
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem (2005) 1.37
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36
Retracted High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest (2007) 1.34
Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res (2006) 1.33
Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem (2002) 1.29
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J (2006) 1.26
Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res (2004) 1.25
A pRb-independent mechanism preserves the postmitotic state in terminally differentiated skeletal muscle cells. J Cell Biol (2004) 1.25
The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J (2009) 1.23
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene (2005) 1.20
Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer (2009) 1.19
Requirement for down-regulation of the CCAAT-binding activity of the NF-Y transcription factor during skeletal muscle differentiation. Mol Biol Cell (2003) 1.19
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem (2010) 1.18
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther (2009) 1.17
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res (2008) 1.17
Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem (2011) 1.16
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis (2002) 1.15
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest (2002) 1.14
PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene (2005) 1.13
Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck (2007) 1.13
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene (2004) 1.12
Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb. Cancer Cell (2002) 1.12
Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta (2008) 1.11
MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem (2003) 1.10
Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res (2012) 1.10
c-Abl acetylation by histone acetyltransferases regulates its nuclear-cytoplasmic localization. EMBO Rep (2006) 1.10
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res (2013) 1.09
Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol (2006) 1.09
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS One (2008) 1.08
HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer (2009) 1.08
Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One (2009) 1.08
Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med (Berl) (2009) 1.08
Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation. Cancer Res (2010) 1.07
Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity. Mol Biol Cell (2008) 1.06
HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell (2012) 1.05
NF-Y dependent epigenetic modifications discriminate between proliferating and postmitotic tissue. PLoS One (2008) 1.05
The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle (2008) 1.05
Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res (2008) 1.05
MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. Oncogene (2002) 1.04
The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. Cancer Res (2007) 1.04
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci U S A (2003) 1.04
Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Radic Biol Med (2010) 1.03
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res (2005) 1.03
HIPKs: Jack of all trades in basic nuclear activities. Biochim Biophys Acta (2008) 1.03
HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett (2005) 1.02
The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One (2011) 1.02
Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res (2010) 1.01
Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia. J Biol Chem (2005) 1.01
Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res (2013) 0.99
Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis. EMBO Rep (2009) 0.99
Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum Mol Genet (2013) 0.97
Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res (2007) 0.96
Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. J Pathol (2009) 0.96
HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation. Biochim Biophys Acta (2013) 0.95
PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res (2011) 0.95
p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle (2009) 0.94
Purification and characterization of adipose-derived stem cells from patients with lipoaspirate transplant. Cell Transplant (2010) 0.94
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin Cancer Res (2006) 0.94
Activation of Vgamma9Vdelta2 T cells by non-peptidic antigens induces the inhibition of subgenomic HCV replication. Int Immunol (2005) 0.93
Retracted Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro. DNA Cell Biol (2009) 0.93
Differential role of transcription-coupled repair in UVB-induced response of human fibroblasts and keratinocytes. Cancer Res (2005) 0.93
Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med (Berl) (2008) 0.92
Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc Natl Acad Sci U S A (2002) 0.91